<DOC>
	<DOC>NCT02200809</DOC>
	<brief_summary>Purpose of the investigators study is to determine the short and medium term histological cancer control of focal therapy using MR-guided focal laser ablation therapy in the treatment of localised prostate cancer.</brief_summary>
	<brief_title>MR-guided Focal Laser Ablation of the Prostate</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Newly diagnosed and biopsy proven prostate cancer Intermediate risk patients (PSA &lt;= 20 ng/mL, Gleason â‰¤ 7, T2b) No previous treatment for prostate cancer Cancer lesion located at least 1 cm away from the neurovascular bundle according to Multimodality MR images Signed informed consent by patient Age 18 years or older Signed screening form (to determine exclusion for metal device/foreign bodies/claustrophobia) Impossibility to obtain a valid informed consent Patients unable to undergo MR imaging, including those with contraindications Contraindications to MR guided focal laser therapy (colitis ulcerosa, rectal pathology or abdomino perineal resection) Metallic hip implant or any other metallic implant or device that distorts local magnetic field and compromises the quality of MR imaging Patients with evidence for nodal or metastatic disease Patients with an estimated Glomerular Filtration Ratio (eGFR) &lt; 40 mL/min/1.73 m2</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>MR-guided therapy</keyword>
	<keyword>Focal laser ablation</keyword>
	<keyword>Prostate cancer</keyword>
</DOC>